Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?
Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO changes at biotech firms.
The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?
Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Editor's Picks
